Adema J, Ahiskali A, Fida M, Mediwala Hornback K, Stevens R, Rivera C
Pathogens. 2023; 12(5).
PMID: 37242373
PMC: 10223386.
DOI: 10.3390/pathogens12050703.
Deshpande D, Srivastava S, Pasipanodya J, Gumbo T
Front Pharmacol. 2022; 13:1024608.
PMID: 36330086
PMC: 9622937.
DOI: 10.3389/fphar.2022.1024608.
Ma H, Cheng J, Peng L, Gao Y, Zhang G, Luo Z
PLoS One. 2020; 15(3):e0230383.
PMID: 32191760
PMC: 7082046.
DOI: 10.1371/journal.pone.0230383.
Galar A, Weil A, Dudzinski D, Munoz P, Siedner M
Clin Microbiol Rev. 2019; 32(2).
PMID: 30760474
PMC: 6431130.
DOI: 10.1128/CMR.00041-18.
Kondo Y, Ueda M, Kobayashi Y, Schwab J
J Arrhythm. 2016; 32(4):297-302.
PMID: 27588153
PMC: 4996843.
DOI: 10.1016/j.joa.2016.02.007.
In vivo interactions of continuous flucloxacillin infusion and high-dose oral rifampicin in the serum of 15 patients with bone and soft tissue infections due to Staphylococcus aureus - a methodological and pilot study.
Garzoni C, Uckay I, Belaieff W, Breilh D, Suva D, Huggler E
Springerplus. 2014; 3:287.
PMID: 25019039
PMC: 4072877.
DOI: 10.1186/2193-1801-3-287.
Influence of rifampin therapy on serum bactericidal activity in the presence of cloxacillin and vancomycin.
Mackenzie A, MacDonald N
Can J Infect Dis. 2012; 1(2):41-7.
PMID: 22553438
PMC: 3327965.
DOI: 10.1155/1990/357189.
Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates.
van der Lugt N, Steggerda S, Walther F
BMC Pediatr. 2010; 10:84.
PMID: 21092087
PMC: 2994847.
DOI: 10.1186/1471-2431-10-84.
Deep recurrent infection of the hip after tumoral resection in an 18-years old male--a case report.
Niculescu M, Negrusoiu M
J Med Life. 2010; 1(4):439-42.
PMID: 20108525
PMC: 3018973.
Rifampin combination therapy for nonmycobacterial infections.
Forrest G, Tamura K
Clin Microbiol Rev. 2010; 23(1):14-34.
PMID: 20065324
PMC: 2806656.
DOI: 10.1128/CMR.00034-09.
Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus.
Riedel D, Weekes E, Forrest G
Antimicrob Agents Chemother. 2008; 52(7):2463-7.
PMID: 18474578
PMC: 2443910.
DOI: 10.1128/AAC.00300-08.
Antibiotics in neonatal infections: a review.
Fanos V, Dallagnola A
Drugs. 1999; 58(3):405-27.
PMID: 10493270
DOI: 10.2165/00003495-199958030-00003.
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.
Palmer S, Rybak M
Antimicrob Agents Chemother. 1996; 40(3):701-5.
PMID: 8851596
PMC: 163183.
DOI: 10.1128/AAC.40.3.701.
Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis.
Perdikaris G, Giamarellou H, Pefanis A, Donta I, Karayiannakos P
Antimicrob Agents Chemother. 1995; 39(10):2289-94.
PMID: 8619584
PMC: 162931.
DOI: 10.1128/AAC.39.10.2289.
In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin.
Giron K, Gross M, Musher D, WILLIAMS Jr T, Tharappel R
Antimicrob Agents Chemother. 1995; 39(12):2798-800.
PMID: 8593023
PMC: 163033.
DOI: 10.1128/AAC.39.12.2798.
Antimicrobial susceptibility of coagulase-negative staphylococci.
Archer G, Climo M
Antimicrob Agents Chemother. 1994; 38(10):2231-7.
PMID: 7840550
PMC: 284723.
DOI: 10.1128/AAC.38.10.2231.
Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus.
Brandt C, Rouse M, Tallan B, Wilson W, Steckelberg J
Antimicrob Agents Chemother. 1994; 38(9):2191-3.
PMID: 7811044
PMC: 284709.
DOI: 10.1128/AAC.38.9.2191.
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
Kang S, Rybak M, McGRATH B, Kaatz G, Seo S
Antimicrob Agents Chemother. 1994; 38(12):2702-9.
PMID: 7695250
PMC: 188273.
DOI: 10.1128/AAC.38.12.2702.
Effective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditis.
Brandt C, Rouse M, Tallan B, Laue N, Wilson W, Steckelberg J
Antimicrob Agents Chemother. 1995; 39(8):1815-9.
PMID: 7486924
PMC: 162831.
DOI: 10.1128/AAC.39.8.1815.
Antagonism between nafcillin or oxacillin and rifampin against Staphylococcus aureus.
Watanakunakorn C, Tisone J
Antimicrob Agents Chemother. 1982; 22(5):920-2.
PMID: 7181497
PMC: 185687.
DOI: 10.1128/AAC.22.5.920.